USAQ on OTC

QHSLab, Inc.

QHSLab, Inc. is an American surgical and medical instruments and apparatus company.1 It is headquartered in West Palm Beach, Florida.1 Its shares trade on OTC under the symbol USAQ.1

Price unavailable

Last updated Oct 20, 2026.

Overview

Compare with OSR Health, Inc., FEMASYS INC or Nuo Therapeutics, Inc., or pick any stock.

  • TickerUSAQ on OTC1
  • IndustrySurgical & Medical Instruments & Apparatus1
  • HeadquartersWest Palm Beach, Florida1
  • Incorporated inNV2
  • Business address901 Northpoint Parkway, Suite 302, West Palm Beach, Fl 334072
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Immunotherapy is designed to gradually desensitize patients to specific allergens through controlled exposure over time.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

67.3%Gross margin4
4.9%Operating margin4
-17.0%Net margin5
26.3%Revenue growth, 20254
-28.1%Return on equity4

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Integrated Service Program brought in 42% of the revenue QHSLab, Inc. broke down this way in fiscal 2025.

  1. Integrated Service Program$1.1M442%up 74% from 2024
  2. Allergy Diagnostic Kit Sales$823.1K431%down 1% from 2024
  3. Immunotherapy Treatment Sales$487.8K418%up 19% from 2024
  4. Clinical Study Revenue$133.7K45%up 0% from 2024
  5. Subscription Revenue$43.7K42%down 20% from 2024
  6. Shipping and Handling$41.7K42%up 16% from 2024
  7. Training and Other Revenue$40.7K42%up 82% from 2024
Products and services by year
Products and services20242025
Integrated Service Program$643.2K$1.1M
Allergy Diagnostic Kit Sales$833.0K$823.1K
Immunotherapy Treatment Sales$409.3K$487.8K
Clinical Study Revenue$133.7K$133.7K
Subscription Revenue$54.5K$43.7K
Shipping and Handling$35.9K$41.7K
Training and Other Revenue$22.3K$40.7K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue33¢$880.9K
  • Research and development18¢$484.9K
  • Other costs40¢$1.1M
  • Interest9¢$237.4K

Out of $2.7M in revenue.45 The company lost money this year.

Financial statements

Revenue67894$2.7M in 2025+2061% since 2020
0$1.0M$2.0M$3.0M2020: $124.5K$124.5K20202021: $1.4M$1.4M2021+1036%2022: $1.2M$1.2M2022−12%2023: $1.4M$1.4M2023+13%2024: $2.1M$2.1M2024+51%2025: $2.7M$2.7M2025+26%
Gross profit67894$1.8M in 2025+3515% since 2020
0$500.0K$1.0M$1.5M$2.0M2020: $50.1K$50.1K20202021: $670.7K$670.7K2021+1239%2022: $619.5K$619.5K2022−8%2023: $793.6K$793.6K2023+28%2024: $1.4M$1.4M2024+71%2025: $1.8M$1.8M2025+33%
Operating income1067894$131.2K in 2025
-$600.0K-$400.0K-$200.0K0$200.0K$400.0K2019: -$154.1K-$154.1K20192020: -$275.1K-$275.1K2020+79%2021: -$502.3K-$502.3K2021+83%2022: -$560.5K-$560.5K2022+12%2023: -$240.2K-$240.2K2023−57%2024: $205.7K$205.7K20242025: $131.2K$131.2K2025−36%
Net income10678945-$457.4K in 2025+175% since 2019
-$1.0M-$750.0K-$500.0K-$250.0K02019: -$166.5K-$166.5K20192020: -$327.4K-$327.4K2020+97%2021: -$770.2K-$770.2K2021+135%2022: -$996.0K-$996.0K2022+29%2023: -$468.4K-$468.4K2023−53%2024: -$259.2K-$259.2K2024−45%2025: -$457.4K-$457.4K2025+76%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Revenue$2.7M$2.1M
Cost of revenue$880.9K$774.0K
Gross profit$1.8M$1.4M
Sales and marketing$683.5K$509.1K
General and administrative$439.1K$276.5K
Research and development$484.9K$294.5K
Amortization$72.1K$72.1K
Total Operating Expenses$1.7M$1.2M
Net operating income$131.2K$205.7K
Interest expense-$237.4K-$465.1K
Other income$82$78
Gain on extinguishment of debt, net$665.8K
Loss on conversion of debt-$102.3K
Income (loss) before income taxes$457.4K-$259.2K
Net income (loss)$457.4K-$259.2K
Basic net earnings (loss) per share$0.04-$0.03
Diluted net earnings (loss) per share$0.02-$0.03
Basic11.3M shares10.3M shares
Diluted19.3M shares10.3M shares

Compare QHSLab, Inc. with another company

Corporate structure

QHSLab, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of QHSLab, Inc.

  • Jeremy L. Smollar Irrevocable Trust dtd 2/13/2023 Filed SCHEDULE 13G on QHSLab, Inc., latest Sep 17, 2026
  • Justin B. Smollar Irrevocable Trust dtd 2/13/2023 Filed SCHEDULE 13G on QHSLab, Inc., latest Sep 10, 2026
  • Marvin Smollar Family Trust dtd 2/13/2023 Filed SCHEDULE 13D/A on QHSLab, Inc., latest Sep 4, 2026 (2 filings since Apr 27, 2026)
  • Nicholas Terrance Peters Filed SCHEDULE 13G/A on QHSLab, Inc., latest Feb 25, 2026 (2 filings since Feb 24, 2026)
  • QHSLab, Inc. West Palm Beach, Florida

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What QHSLab, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Computer equipment and software$223.4K4 Dec 31, 2025$223.4K4 Dec 31, 20240%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$636.2K4 Dec 31, 2025$157.2K4 Dec 31, 2024+304.8%

Intangibles and goodwill

ItemLatestA year beforeChange
Finite-lived intangibles, gross$1.6M4 Dec 31, 2025$1.6M4 Dec 31, 20240%
Accumulated amortization$324.5K4 Dec 31, 2025$252.4K4 Dec 31, 2024+28.6%
Finite-lived intangibles, net$1.3M4 Dec 31, 2025$1.4M4 Dec 31, 2024−5.3%

Inventory

ItemLatestA year beforeChange
Inventory, total$35.8K4 Dec 31, 2025$41.8K4 Dec 31, 2024−14.3%

Leadership

Who has led QHSLab, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Richard J. Rubin2008–2009
  2. Troy James Grogan2020–now

Chair

  1. Richard J. Rubin2008

President

  1. Troy James Grogan2020–now

Chief financial officer

  1. Richard J. Rubin2009
2010201520202025
Board members and other officers (2)

Former names

  • USA EQUITIES CORP.Nov 23, 2015 to Apr 19, 20222
  • AMERICAN BIOGENETIC SCIENCES INCMay 14, 1996 to Nov 16, 20152

Timeline

  1. Aug 3, 20268-K Regulation FD disclosure16
  2. Jun 17, 20268-K Regulation FD disclosure17
  3. May 26, 20268-K Regulation FD disclosure18
  4. Apr 21, 20268-K Regulation FD disclosure19
  5. Mar 31, 20268-K Regulation FD disclosure20
  6. Jan 26, 20268-K Regulation FD disclosure21
  7. Jan 23, 20268-K Entered a material agreement; Unregistered sale of shares; Other events22
  8. Jan 16, 20268-K Regulation FD disclosure23
  9. Jan 6, 20268-K Regulation FD disclosure24
  10. Jan 2, 20268-K Entered a material agreement; Unregistered sale of shares25
  11. Dec 29, 20258-K Entered a material agreement; Unregistered sale of shares; Regulation FD disclosure26
  12. Dec 3, 20258-K Regulation FD disclosure27
  13. Feb 21, 2020New chief executive Troy James Grogan becomes CEO12
  14. Mar 5, 2008New chief executive Richard J. Rubin becomes CEO13

Filings

99 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 60 major events, 3 insider forms, 6 large holders, 1 private raises, 9 other. The latest 20:

  1. Sep 17, 2026SCHEDULE 13G EDGAR
  2. Sep 10, 2026SCHEDULE 13G EDGAR
  3. Sep 4, 2026SCHEDULE 13D/A EDGAR
  4. Sep 3, 20264 PRIMARY DOCUMENT EDGAR
  5. Aug 12, 202610-Q EDGAR
  6. Aug 3, 20268-K EDGAR
  7. Jun 17, 20268-K EDGAR
  8. May 26, 20268-K EDGAR
  9. May 14, 202610-Q EDGAR
  10. Apr 29, 20263 PRIMARY DOCUMENT EDGAR
  11. Apr 27, 2026SCHEDULE 13D EDGAR
  12. Apr 21, 20268-K EDGAR
  13. Mar 31, 20268-K EDGAR
  14. Mar 30, 202610-K EDGAR
  15. Feb 25, 2026SCHEDULE 13G/A EDGAR
  16. Feb 24, 2026SCHEDULE 13G EDGAR
  17. Feb 13, 20265 EDGAR
  18. Jan 26, 20268-K EDGAR
  19. Jan 23, 20268-K EDGAR
  20. Jan 16, 20268-K EDGAR

The 99 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Dec 26, 2025Raised $626,548 in a private offering of equity Form D: $700,000 offered in all Form D

SEC filer profile

How QHSLab, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARQHSLab, Inc.1
  • CIK0000856984
  • Employer ID (EIN)30-11043013
  • Filer statusNon- accelerated filer not an emerging growth company; a smaller reporting company; a shell company3
  • Incorporated inNevada3
  • Fiscal year endsDecember 311
  • Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address901 Northpoint Parkway, Suite 302, West Palm Beach, FL 334071
  • Phone(929) 379-65031
  • Shares outstanding15,032,788 as of Aug 12, 20265
  • Public float$1.6M as of Jun 30, 20253
  • AuditorAstra Audit & Advisory LLC, Tampa, Florida PCAOB ID 6920; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceFeb 14, 19961
  • Filings360 in all: 8-K (115), 10-Q (76), 10-K (22), 10QSB (16), NT 10-Q (12), S-3 (10), 424B3 (7), DEF 14A (7)1
    All 41 form types

    NT 10-K (7), 10KSB (6), UPLOAD (6), S-8 (5), 10-Q/A (4), 3 (4), CORRESP (4), DEF 14C (4), PRE 14A (4), PRE 14C (4), S-3/A (4), SC 13D (4), SC 13D/A (4), 10-K/A (3), 5 (3), SC 13G/A (3), SCHEDULE 13G (3), 10-K405 (2), 10KSB/A (2), 4 (2), 8-K/A (2), D (2), EFFECT (2), S-1 (2), 10-K405/A (1), DEFR14A (1), DEFS14A (1), PRER14A (1), PRES14A (1), S-1/A (1), SCHEDULE 13D (1), SCHEDULE 13D/A (1), SCHEDULE 13G/A (1)

  • Latest filingsAnnual report (10-K) Mar 30, 2026
    Quarterly report (10-Q) Aug 12, 2026
    Proxy statement (DEF 14A) May 15, 2001
    Latest 8-K (8-K) Aug 3, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.0001 Par ValueUSAQ

From the cover page of the 10-K filed Mar 30, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks QHSLab, Inc. names in Item 1A of its 10-K filed Mar 30, 2026: 42 risks under these headings, as written.3

  • Risks Related to Our Business
  • Although we achieved net income in 2025, we incurred net losses in 2024 and prior periods and may not be able to sustain profitability or continue operating as a going concern.
  • We may need additional financing to grow our business.
  • We are an early stage company with a short operating history and a relatively new business model in an emerging and rapidly evolving market, which makes it difficult to evaluate our future prospects.
  • We are not generating sufficient revenues to achieve our business plan.
  • All of our revenues have been generated from a limited number of product lines.
  • We are dependent upon third parties for our products.
  • We have engaged in limited product development and our product development efforts may not result in commercial products.
  • There is no assurance we can generate significant positive cash flow or operating profits as our operations grow.
  • If we fail to raise additional capital, our ability to implement our business plan and strategy could be compromised.
  • If we issue additional shares of common stock, it would reduce our stockholders’ percentage of ownership and may dilute our share value.
  • Dependence on Key Existing and Future Personnel.
The other 31 risks
  • Our sole officer and director is engaged in other business activities and has a conflict in determining how much time to devote to our affairs. His failure to devote sufficient time to our business could have a negative impact on our operations.
  • We operate in a highly competitive industry.
  • We face substantial competition, and others may discover, develop, acquire or commercialize competitive products before or more successfully than we do.
  • The growth of our business relies, in part, on the growth and success of our clients.
  • We conduct business in a heavily regulated industry and if we fail to comply with applicable laws and government regulations, we could incur penalties or be required to make significant changes to our operations or experience adverse publicity, which could have a material adverse effect on our business, financial condition, and results of operations.
  • Developments in the healthcare industry could adversely affect our business.
  • Our use and disclosure of personally identifiable information, including health information, is subject to federal and state privacy and security regulations, and our failure to comply with those regulations or to adequately secure the information we hold could result in significant liability or reputational harm and, in turn, a material adverse effect on our client base, membership base and revenue.
  • The security of our platform, networks or computer systems may be breached, and any unauthorized access to our customer data will have an adverse effect on our business and reputation.
  • Because we rely on the internet to interact with our clients, we are subject to extensive and highly-evolving regulations and any adverse changes to, or our failure to comply with, any laws and regulations could adversely affect our brand, reputation, business, operating results, and financial condition.
  • To the extent we use “open source” software, our use could adversely affect our ability to offer our services and subject us to possible litigation.
  • Assertions by third parties of infringement or other violations by us of their intellectual property rights could result in significant costs and harm our business and operating results.
  • Natural disasters, unusually adverse weather conditions, pandemic outbreaks, terrorist acts, conflicts between nations and the response of governments to such occurrences, could impair our ability to purchase, receive or replenish inventory or raw materials or could cause US agencies and insurance companies to modify reimbursement policies, which could result in lost sales, reduced revenues and otherwise adversely affect our financial performance.
  • Our ability to finance our business may be materially adversely affected by global geopolitical conditions including those resulting from the ongoing Russia-Ukraine conflict, the US-Iran conflict, the Israel-Hamas conflict, efforts by terrorist organizations to disrupt global shipping patterns and actions by the United States government to reduce its deficit and influence actions of other nations.
  • Risks Related to Regulation
  • Our products may be subject to product liability legal claims, which could have an adverse effect on our business, results of operations and financial condition.
  • There is significant uncertainty in the healthcare industry in which we operate, and we are subject to the possibility of changing government regulations, which may adversely impact our business, financial condition and results of operations.
  • Compliance with changing regulation of corporate governance and public disclosure will result in significant additional expenses.
  • We may be subject to false or fraudulent claim laws.
  • We are subject to the Stark Law, which may result in significant penalties.
  • If our products fail to comply with evolving government and industry standards and regulations, we may have difficulty selling our products.
  • Risks related to our Common Stock
  • There is not now, and there may never be, an active market for our common stock.
  • Our stock price is likely to be highly volatile because of several factors, including a limited public float.
  • Our stock price may be adversely impacted by natural disasters (whether or not caused by climate change), unusually adverse weather conditions, pandemic outbreaks, terrorist acts, conflicts between nations and terrorist organizations, actions taken by governments such as the imposition of tariffs to impact economics, and the response of the governments of the countries affected by such occurrences.
  • Our common stock is subject to the “Penny Stock” Rules of the SEC, which makes transactions in our stock cumbersome and may reduce the value of an investment in our stock.
  • Shares eligible for future sale may adversely affect the market.
  • Our sole director and officer controls a majority of the votes which may be cast at a meeting of our stockholders.
  • Under our Certificate of Incorporation, our director has the authority, without stockholder approval, to issue preferred stock with terms that may not be beneficial to common stockholders and with the ability to adversely affect stockholder voting power and perpetuate the board’s control over our company.
  • We incur significant costs as a result of operating as a public company and our management will have to devote substantial time to public company compliance obligations.
  • Because we do not intend to pay any cash dividends on our common stock, our stockholders will not be able to receive a return on their shares unless they sell them.
  • We are a “Smaller Reporting Company” with reduced disclosure requirements which may make our common stock less attractive to investors.
  • Limitations on director and officer liability and indemnification of our officers and directors by our articles of incorporation, as amended, and by-laws it may discourage stockholders from bringing suit against an officer or director.
  • We are responsible for the indemnification of our officers and directors.

Legal proceedings

We are currently not a party to any material legal or administrative proceedings and are not aware of any pending legal or administrative proceedings against us. We may from time to time become a party to various legal or administrative proceedings arising in the ordinary course of our business.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31